BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32738410)

  • 1. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Mani RS; Ciniero G; Tuszynski JA; Weinfeld M; West FG
    Eur J Med Chem; 2020 Oct; 204():112658. PubMed ID: 32738410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
    J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
    Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
    Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
    Gentile F; Barakat KH; Tuszynski JA
    Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.
    Chapman TM; Gillen KJ; Wallace C; Lee MT; Bakrania P; Khurana P; Coombs PJ; Stennett L; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4097-103. PubMed ID: 26318993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
    Jordheim LP; Barakat KH; Heinrich-Balard L; Matera EL; Cros-Perrial E; Bouledrak K; El Sabeh R; Perez-Pineiro R; Wishart DS; Cohen R; Tuszynski J; Dumontet C
    Mol Pharmacol; 2013 Jul; 84(1):12-24. PubMed ID: 23580445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM; Melton DW
    Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
    Ciniero G; Elmenoufy AH; Gentile F; Weinfeld M; Deriu MA; West FG; Tuszynski JA; Dumontet C; Cros-Perrial E; Jordheim LP
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):259-267. PubMed ID: 33399940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain mapping of the DNA binding, endonuclease, and ERCC1 binding properties of the human DNA repair protein XPF.
    McCutchen-Maloney SL; Giannecchini CA; Hwang MH; Thelen MP
    Biochemistry; 1999 Jul; 38(29):9417-25. PubMed ID: 10413517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCAF7 is required for maintaining the cellular levels of ERCC1-XPF and nucleotide excision repair.
    Kawara H; Akahori R; Wakasugi M; Sancar A; Matsunaga T
    Biochem Biophys Res Commun; 2019 Oct; 519(1):204-210. PubMed ID: 31493872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.
    Tsodikov OV; Enzlin JH; Schärer OD; Ellenberger T
    Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11236-41. PubMed ID: 16076955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF.
    Chapman TM; Wallace C; Gillen KJ; Bakrania P; Khurana P; Coombs PJ; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4104-8. PubMed ID: 26321360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
    DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
    Kirschner K; Melton DW
    Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells.
    Niedernhofer LJ; Essers J; Weeda G; Beverloo B; de Wit J; Muijtjens M; Odijk H; Hoeijmakers JH; Kanaar R
    EMBO J; 2001 Nov; 20(22):6540-9. PubMed ID: 11707424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.